Abstract
A 4-weekly schedule of Pegylated Liposomal Doxorubicin (PLD) has been approved for the treatment of Metastatic Breast Cancer (MBC). Phase II trials have suggested interest for a 2-weekly regimen. The aim of this study was to compare efficacy and safety of these two modalities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
